
protein kinase inhibitorIndian prescription status not found in lists checkedJan Aushadhi listed
Cabozantinib
काबोज़ान्टिनिब
This page covers the capsules form only, as described in the EU product information. Other forms of cabozantinib sold in India may differ.
Cabozantinib is an anticancer protein kinase inhibitor. The EU product information reviewed covers Cometriq capsules for adults with progressive, unresectable or metastatic medullary thyroid carcinoma. It must be started by a specialist and often needs dose changes because of side effects.
- Generic name
- Cabozantinib
- Used for
- Treating progressive, advanced or metastatic medullary thyroid cancer in adults (Cometriq capsules, EU label).
- Label used
- EU product information (EMA EPAR cometriq), retrieved 2026-10-15
- Prescription status (India)
- Not found in the Schedule H/H1/X/G lists we checked
- On NLEM 2022
- Not found in the list we checked
- NPPA price ceiling
- Not listed in the lists we checked
More facts
- Jan Aushadhi
- Listed (3 product rows)
- Banned combinations
- None found in the list we checked
Compiled from official drug labels and Indian government sources. Always follow your doctor's or pharmacist's advice.
Safety at a glance
- AlcoholNot mentioned in label text
- PregnancyAvoid, per label textSee wording
- BreastfeedingNot mentioned in label text
- DrivingNot mentioned in label text
- KidneyNot mentioned in label text
- LiverCaution in label textSee wording
Taken only from the label text cited on this page. "Not mentioned" does not mean safe. Ask your doctor or pharmacist.
What is cabozantinib used for?
This page uses EU product information (EMA) for Cometriq capsules. The label describes use in adults with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.
Where RET mutation status is unknown or negative, the label says a possible lower benefit should be considered before treatment.
- Medullary thyroid carcinoma that is progressive, unresectable or metastatic
It is a cancer medicine for advanced medullary thyroid cancer in adults.
Source1
How does cabozantinib work?
Cabozantinib is a small molecule that blocks several receptor tyrosine kinases involved in tumour growth, blood vessel formation, bone remodelling and spread.
It was identified as an inhibitor of MET and VEGF receptors, and also blocks others such as RET and AXL.
It blocks several signals that help tumours grow and spread.
Source1
How is cabozantinib usually taken?
This page covers the capsules label only (route: ). Dosing for other forms differs, and the prescriber decides which one you use.
This is label-level information, not personal advice. Indian pack labels may differ, and your prescriber's instruction always comes first.
This page covers the oral capsule (Cometriq). The label says treatment should be started by a physician experienced with anticancer medicines. The labelled dose is 140 mg once daily as one 80 mg and three 20 mg capsules, continuing until no further benefit or unacceptable toxicity.
The label says capsules and Cabometyx tablets are not bioequivalent and must not be used interchangeably. It expects most patients to need one or more dose reductions or interruptions, with reduced doses described as 100 mg then 60 mg daily.
Patients should be closely monitored during the first eight weeks. Interruptions are described for grade 3 or greater toxicities or intolerable grade 2 toxicities.
- Specialist-initiated anticancer therapy
- Not interchangeable with Cabometyx tablets
- Dose reductions or interruptions are common
- Close monitoring in the first eight weeks
The label describes specialist-led daily capsule treatment with frequent dose adjustments.
Source1
What are the side effects of cabozantinib?
Common
- Reactions in at least 20% of patients include diarrhoea, palmar-plantar erythrodysaesthesia (hand-foot syndrome), weight loss, reduced appetite, nausea, fatigue, taste change, hair colour change, hypertension, mouth sores, constipation and vomiting.
- Diarrhoea, nausea, vomiting
- Hand-foot skin reaction
- Fatigue and reduced appetite
- High blood pressure
- Mouth sores and taste change
Serious: get help
- The most common serious reactions listed are pneumonia, mucosal inflammation, low calcium, trouble swallowing, dehydration, pulmonary embolism and high blood pressure.
Common effects include diarrhoea, hand-foot reactions, tiredness and high blood pressure; serious effects can occur.
Source1
Who should be careful with cabozantinib?
The label recommends liver tests before and during treatment, and warns of serious gut perforations, fistulas and abscesses, sometimes fatal. People with recent radiotherapy, inflammatory bowel disease or tumour in airways or oesophagus need careful evaluation.
It is contraindicated with hypersensitivity to the active substance or excipients.
Women of childbearing potential must avoid pregnancy; effective contraception is advised during therapy and for at least 4 months after. Oral contraceptives should be combined with another method. Animal studies showed embryo-foetal and teratogenic effects.
- Liver function monitoring
- Gut perforation and fistula risk
- Contraindicated if hypersensitive
- Avoid pregnancy; contraception for 4 months after
- Close monitoring in the first eight weeks
It needs liver monitoring, carries gut perforation risk, and pregnancy must be avoided.
Source1
What medicines interact with cabozantinib?
- Strong CYP3A4 inhibitors: caution
- Strong CYP3A4 inducers: avoid
- Grapefruit juice: caution
- St. John's Wort: avoid
- Strong CYP3A4 inhibitors such as ritonavir, itraconazole, erythromycin, clarithromycin and grapefruit juice should be approached with caution because they raise cabozantinib levels.
- Strong CYP3A4 inducers such as phenytoin, carbamazepine, rifampicin, phenobarbital and St.
- John's Wort should be avoided in chronic use because they lower levels.
No match in this label text. Ask your pharmacist about any medicine you take.
Drugs and foods that change CYP3A4 activity can raise or lower its levels.
Source1
How should cabozantinib be stored?
The label also says to keep it away from moisture.
Follow the storage line on your own pack, and keep medicines out of the reach of children.
Follow the storage instructions on your pack.
Source1
Is cabozantinib a prescription medicine in India?
We did not find cabozantinib in the Drugs Rules 1945 Schedule H, H1, X or G rows we checked, so we cannot state its Indian prescription status from our lists. Ask your pharmacist or doctor.
We did not find cabozantinib on the National List of Essential Medicines 2022 in the list we checked.
The Jan Aushadhi (PMBJP) list we checked has 3 product rows that mention cabozantinib. We did not capture prices for them.
We did not find cabozantinib in the Schedule H, H1, X or G rows we checked, not found on NLEM 2022.
Source2
What is the price ceiling for cabozantinib?
Jan Aushadhi lists cabozantinib products including Cabozantinib Tablets 20 mg 20 mg; Cabozantinib Tablets 40 mg 40 mg; Cabozantinib Tablets 60 mg 60 mg. We have not shown a price for them. Check the pack and the seller for the actual price.
NPPA lists per-unit ceilings where a formulation is scheduled. Check the pack and seller.
Source2
Frequently asked questions
Can I drink alcohol while taking cabozantinib?
The label we reviewed does not say. Ask your doctor or pharmacist.
Source1
Is cabozantinib safe in pregnancy and breastfeeding?
The label says avoid pregnancy and use effective contraception during and for at least 4 months after therapy. Animal studies showed harm. Ask your doctor or pharmacist.
Source1
Should cabozantinib be taken with food?
The label advises caution with grapefruit juice. It does not otherwise say here. Ask your doctor or pharmacist.
Source1
Can cabozantinib affect driving or alertness?
The label we reviewed does not say. Ask your doctor or pharmacist.
Source1
Can children or older adults take cabozantinib?
The label we reviewed covers adult use only. Ask your doctor or pharmacist about older adults or children.
Source1
Is cabozantinib on the NLEM and Jan Aushadhi list?
We did not find it on NLEM 2022. Yes, several cabozantinib products are in the Jan Aushadhi list we checked.
Source2
Sources
- 1EMA European Public Assessment Report: product information (EU) (cometriq) Open source · 2026-10-15
- 2PMBJP (Jan Aushadhi) product list (p86:sno1875) Open source · 2026-10-15
Compiled by software from the sources above and checked by automated rules. Last checked: 2026-10-15 · How we use sources · Report a correction
This information is educational and is not a substitute for advice from your doctor or pharmacist. It does not tell you what dose you personally should take. In an emergency call 112.